The association of idiopathic recurrent pregnancy loss with polymorphisms in hemostasis-related genes

Gene

Volumn 530, Issue 2, 2013, Pages 248-252

  Cao, Yunlei ^a,b   Zhang, Zhaofeng ^b   Xu, Jianhua ^b   Yuan, Wei ^b   Wang, Jian ^b   Huang, Xianliang ^a,b   Shen, Yueping ^c   Du, Jing ^b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^c SOOCHOW UNIVERSITY   (China)

Author keywords

Annexin A5; Antithrombin; Factor II; Factor V; Thrombomodulin; Tissue factor pathway inhibitor

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5; LIPOCORTIN 5; PROTHROMBIN; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; GESTATIONAL AGE; HEMOSTASIS; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECURRENT ABORTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SPONTANEOUS ABORTION; THROMBOEMBOLISM; THROMBOPHILIA;

ACTIVATED PROTEIN C; ANNEXIN A5; ANTITHROMBIN; ANXA5; APC; BMI; BODY MASS INDEX; CI; CONFIDENCE INTERVAL; FACTOR II; FACTOR V; ODDS RATIO; OR; RECURRENT PREGNANCY LOSS; RPL; SERPINC1; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; TFPI; THBD; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR;

ABORTION, HABITUAL; ADULT; ALLELES; ANNEXIN A5; ANTITHROMBIN III; CASE-CONTROL STUDIES; FACTOR V; FEMALE; GENE FREQUENCY; HEMOSTASIS; HUMANS; LIPOPROTEINS; LOGISTIC MODELS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; PROTHROMBIN; RISK FACTORS; THROMBOMODULIN;

EID: 84884532183     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.07.080     Document Type: Article

References (36)

1. Aleksic N., Folsom A.R., Cushman M., Heckbert S.R., Tsai M.Y., Wu K.K. Prospective study of the A455V polymorphism in the thrombomodulin gene, plasma thrombomodulin, and incidence of venous thromboembolism: the LITE Study. J. Thromb. Haemost. 2003, 1:88-94.
2. Ameziane N., et al. The -33T->C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations. Thromb. Haemost. 2002, 88:195-199.
3. Anon. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil. Steril. 2013, 99:63.
4. Battinelli E.M., Bauer K.A. Thrombophilias in pregnancy. Hematol. Oncol. Clin. North Am. 2011, 25:323-333. (viii).
5. Bezemer I.D., et al. Gene variants associated with deep vein thrombosis. JAMA 2008, 299:1306-1314.
6. Bogdanova N., et al. A common haplotype of the annexin A5 (ANXA5) gene promoter is associated with recurrent pregnancy loss. Hum. Mol. Genet. 2007, 16:573-578.
7. Brenner B., Sarig G., Weiner Z., Younis J., Blumenfeld Z., Lanir N. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb. Haemost. 1999, 82:6-9.
8. Cavalli-Sforza L.L., Menozzi P., Piazza A. Demic expansions and human evolution. Science 1993, 259:639-646.
9. Crawley J.T., Lane D.A. The haemostatic role of tissue factor pathway inhibitor. Arterioscler. Thromb. Vasc. Biol. 2008, 28:233-242.
10. Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008, 112:19-27.
11. Dahm A., Van H.V., Bendz B., Rosendaal F., Bertina R.M., Sandset P.M. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003, 101:4387-4392.
12. Faul F., Erdfelder E., Buchner A., Lang A.G. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav. Res. Methods 2009, 41:1149-1160.
13. Franchini M., Veneri D. Inherited thrombophilia: an update. Clin. Lab 2005, 51:357-365.
14. Gabriel S., Ziaugra L., Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr. Protoc. Hum. Genet. 2009, (Chapter 2: Unit 2.12).
15. Gehring N.H., et al. Increased efficiency of mRNA 3' end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat. Genet. 2001, 28:389-392.
16. Gerke V., Moss S.E. Annexins: from structure to function. Physiol. Rev. 2002, 82:331-371.
17. Guerra-Shinohara E.M., et al. Polymorphisms in antithrombin and in tissue factor pathway inhibitor genes are associated with recurrent pregnancy loss. Thromb. Haemost. 2012, 108:693-700.
18. Heit J.A., Petterson T.M., Owen W.G., Burke J.P., DE Andrade M., Melton L.J. Thrombomodulin gene polymorphisms or haplotypes as potential risk factors for venous thromboembolism: a population-based case-control study. J. Thromb. Haemost. 2005, 3:710-717.
19. Hoke M., et al. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thromb. Haemost. 2005, 94:787-790.
20. Kalafatis M., Rand M.D., Mann K.G. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J. Biol. Chem. 1994, 269:31869-31880.
21. Li T.C., Makris M., Tomsu M., Tuckerman E., Laird S. Recurrent miscarriage: aetiology, management and prognosis. Hum. Reprod. Update 2002, 8:463-481.
22. Long J.C., Caceres J.F. The SR protein family of splicing factors: master regulators of gene expression. Biochem. J. 2009, 417:15-27.
23. Martinelli I. Risk factors in venous thromboembolism. Thromb. Haemost. 2001, 86:395-403.
24. Navarro S., et al. Association of the Thrombomodulin Gene c.1418C>T Polymorphism With Thrombomodulin Levels and With Venous Thrombosis Risk. Arterioscler. Thromb. Vasc. Biol. 2013, 33(6):1435-1440.
25. Okon M.A., Laird S.M., Tuckerman E.M., Li T.C. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertil. Steril. 1998, 69:682-690.
26. Opstad T.B., Eilertsen A.L., Hoibraaten E., Skretting G., Sandset P.M. Tissue factor pathway inhibitor polymorphisms in women with and without a history of venous thrombosis and the effects of postmenopausal hormone therapy. Blood Coagul. Fibrinolysis 2010, 21:516-521.
27. Rai R., Regan L. Recurrent miscarriage. Lancet 2006, 368:601-611.
28. Rey E., Kahn S.R., David M., Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003, 361:901-908.
29. Sabadell J., Casellas M., Alijotas-Reig J., Arellano-Rodrigo E., Cabero L. Inherited antithrombin deficiency and pregnancy: maternal and fetal outcomes. Eur. J. Obstet. Gynecol. Reprod. Biol. 2010, 149:47-51.
30. Shi Y.Y., He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005, 15:97-98.
31. Slatkin M. Inbreeding coefficients and coalescence times. Genet. Res. 1991, 58:167-175.
32. Smith P.J., Zhang C., Wang J., Chew S.L., Zhang M.Q., Krainer A.R. An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum. Mol. Genet. 2006, 15:2490-2508.
33. Stephenson M., Kutteh W. Evaluation and management of recurrent early pregnancy loss. Clin. Obstet. Gynecol. 2007, 50:132-145.
34. Sugiyama S., et al. Haplotype of thrombomodulin gene associated with plasma thrombomodulin level and deep vein thrombosis in the Japanese population. Thromb. Res. 2007, 119:35-43.
35. Tang L., et al. Common genetic risk factors for venous thrombosis in the Chinese population. Am. J. Hum. Genet. 2013, 92:177-187.
36. Zakai N.A., Lutsey P.L., Folsom A.R., Heckbert S.R., Cushman M. Total tissue factor pathway inhibitor and venous thrombosis. The Longitudinal Investigation of Thromboembolism Etiology. Thromb. Haemost. 2010, 104:207-212.